Anavex Life Sciences has announced promising results from a 48-week Phase 2 extension study
evaluating ANAVEX®2-73 (blarcamesine) in patients with Parkinson’s disease
dementia. The study achieved both its primary and secondary objectives,
demonstrating significant clinical benefits. 

The study, known as ANAVEX2-73-PDD-EP-001, assessed safety, tolerability, and several efficacy
endpoints, including the Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) and the Montreal Cognitive Assessment (MoCA). Patients
on ANAVEX®2-73 exhibited improvements in all these measures over the 48-week period. 

Dr. Christopher U Missling, CEO of Anavex Life Sciences, commented on the findings, noting the potential
impact of ANAVEX®2-73 on slowing and possibly reversing Parkinson’s disease
symptoms. This study marks an important step in the continued development of
therapies targeting neurodegenerative diseases. 

The open-label extension phase followed a double-blind, placebo-controlled trial, allowing
participants to continue their anti-Parkinson’s medication regimen. Notably,
the study included a ‘drug holiday’ period due to COVID-19 delays, which
provided additional insights. During this period, patients experienced a
worsening of symptoms, which later improved upon resuming ANAVEX®2-73 treatment. 

Importantly, the safety profile of ANAVEX®2-73 remained consistent with previous studies, underscoring its
potential for long-term use. The successful outcomes pave the way for a pivotal
trial, which Anavex Life Sciences plans to initiate soon. 

Anavex Life Sciences is committed to advancing its therapeutic portfolio, which includes
ANAVEX®2-73 for Alzheimer’s disease and Rett syndrome, among others. The
company continues to focus on developing innovative treatments for central
nervous system disorders. 

This latest study reaffirms Anavex’s position in the biopharmaceutical landscape and highlights
its ongoing efforts to address critical unmet medical needs. Like this page on Facebook, for more information. 

Find more information about Anavex Life Sciences on https://finance.yahoo.com/quote/AVXL/